An Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics and Conspicuity of Bludigo® When Used As an Aid in the Determination of Ureteral Patency in Pediatric Patients
Latest Information Update: 05 Mar 2025
Price :
$35 *
At a glance
- Drugs Indigotindisulfonate sodium (Primary)
- Indications Kidney disorders
- Focus Therapeutic Use
- Sponsors Provepharm
- 28 Feb 2025 Planned End Date changed from 1 Feb 2025 to 1 Jan 2026.
- 28 Feb 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Dec 2025.
- 28 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Apr 2025.